RecruitingPhase 1NCT03760575

Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)

Studying Pleural mesothelioma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Abramson Cancer Center at Penn Medicine
Principal Investigator
Corey Langer, MD
University of Pennsylvania Abramson Cancer Center
Intervention
Pembrolizumab(drug)
Enrollment
20 target
Eligibility
18 years · All sexes
Timeline
20232027

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03760575 on ClinicalTrials.gov

Other trials for Pleural mesothelioma

Additional recruiting or active studies for the same condition.

See all trials for Pleural mesothelioma

← Back to all trials